We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$3B
1-Year Est. Return
46.72%
This Fund
S&P 500
This Quarter
Est. Return
+5.48%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.53B
AUM Growth
+$340M
(+11%)
Cap. Flow
-$961M
Cap. Flow
% of AUM
-27.24%
Top 10 Holdings %
Top 10 Hldgs %
34.64%
Holding
91
New
15
Increased
24
Reduced
22
Closed
8
Top Buys
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$93.1M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$47M |
| 3 |
BCAX
Bicara Therapeutics
BCAX
|
+$42.3M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$39.9M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$39M |
Top Sells
| 1 |
EXAS
Exact Sciences
EXAS
|
+$48.3M |
| 2 |
Vaxcyte
PCVX
|
+$46M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$39M |
| 4 |
Apogee Therapeutics
APGE
|
+$35.9M |
| 5 |
argenx
ARGX
|
+$35.5M |
Sector Composition
| 1 | Healthcare | 65.68% |
| 2 | Consumer Staples | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$6.44B
| $120M | 3.39% |
3,170,875
-138,632
| -4% | -$4.86M |
|
2
Xenon Pharmaceuticals
XENE
$6.55B
| $107M | 3.02% |
2,707,255
+146,682
| +6% | +$5.91M |
|
3
Neurocrine Biosciences
NBIX
$17.3B
| $106M | 3% |
917,674
+158,665
| +21% | +$21.8M |
|
|
4
Apogee Therapeutics
APGE
$10.2B
| $96.5M | 2.74% |
1,643,226
-748,816
| -31% | -$35.9M |
|
|
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
| $90.1M | 2.55% |
3,125,183
+2,513,383
| +411% | +$93.1M |
|
6
Align Technology
ALGN
$13B
| $79.3M | 2.25% |
311,679
+36,472
| +13% | +$8.61M |
|
7
Guardant Health
GH
$21.6B
| $76.7M | 2.17% |
3,342,124
+534,156
| +19% | +$15.1M |
|
8
Legend Biotech
LEGN
$4.46B
| $75.1M | 2.13% |
1,541,551
-128,169
| -8% | -$6.83M |
|
9
Viking Therapeutics
VKTX
$4.39B
| $73.2M | 2.08% |
1,156,977
+50,072
| +5% | +$2.94M |
|
10
Kiniksa Pharmaceuticals
KNSA
$4.75B
| $72.3M | 2.05% |
2,894,513
+836,210
| +41% | +$20.4M |
|
11
Penumbra
PEN
$12.5B
| $70.2M | 1.99% |
361,428
+148,834
| +70% | +$28.1M |
|
12
Maravai LifeSciences
MRVI
$1.04B
| $69.4M | 1.97% |
8,353,287
-670,750
| -7% | -$5.8M |
|
|
DAWN
13
DELISTED
Day One Biopharmaceuticals
DAWN
| $67.9M | 1.92% |
4,873,853
+1,837,949
| +61% | +$26.2M |
|
14
Spyre Therapeutics
SYRE
$8.86B
| $64.4M | 1.83% |
2,189,836
-324,702
| -13% | -$9.04M |
|
15
Repligen
RGEN
$8.35B
| $59M | 1.67% |
396,781
+73,272
| +23% | +$10.5M |
|
16
iRhythm Holdings
IRTC
$3.72B
| $58.1M | 1.65% |
782,557
+256,200
| +49% | +$20.4M |
|
|
17
argenx
ARGX
$54B
| $52.4M | 1.49% |
96,724
-70,200
| -42% | -$35.5M |
|
|
18
Edgewise Therapeutics
EWTX
$4.39B
| $52.3M | 1.48% |
+1,958,310
| New | +$39M |
|
19
Inspire Medical Systems
INSP
$1.46B
| $50.4M | 1.43% |
238,911
-140,532
| -37% | -$24.4M |
|
|
20
Sarepta Therapeutics
SRPT
$1.86B
| $46.3M | 1.31% |
370,400
+288,500
| +352% | +$39.9M |
|
21
Intuitive Surgical
ISRG
$138B
| $44.9M | 1.27% |
91,300
-9,200
| -9% | -$4.28M |
|
|
AVDL
22
DELISTED
Avadel Pharmaceuticals
AVDL
| $44.4M | 1.26% |
3,388,939
+490,300
| +17% | +$7.47M |
|
|
BCAX
23
Bicara Therapeutics
BCAX
$1.85B
| $42.2M | 1.2% |
+1,657,600
| New | +$42.3M |
|
24
Keros Therapeutics
KROS
$218M
| $41.1M | 1.16% |
707,240
-274,969
| -28% | -$13.6M |
|
25
Glaukos
GKOS
$9.21B
| $40.6M | 1.15% |
311,616
-184,960
| -37% | -$23M |
|
Similar funds
NC
VVP
SP
DIG
ECP
PCM
ROTUOC
SM